JP2024534066A5 - - Google Patents
Info
- Publication number
- JP2024534066A5 JP2024534066A5 JP2024509404A JP2024509404A JP2024534066A5 JP 2024534066 A5 JP2024534066 A5 JP 2024534066A5 JP 2024509404 A JP2024509404 A JP 2024509404A JP 2024509404 A JP2024509404 A JP 2024509404A JP 2024534066 A5 JP2024534066 A5 JP 2024534066A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- approximately
- lipid
- lipid nanoparticles
- nanoparticles according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021902567 | 2021-08-17 | ||
| AU2021902567A AU2021902567A0 (en) | 2021-08-17 | Lipid nanoparticle formulations | |
| PCT/AU2022/050913 WO2023019310A1 (en) | 2021-08-17 | 2022-08-17 | Lipid nanoparticle formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534066A JP2024534066A (ja) | 2024-09-18 |
| JP2024534066A5 true JP2024534066A5 (https=) | 2025-10-21 |
Family
ID=85239260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509404A Pending JP2024534066A (ja) | 2021-08-17 | 2022-08-17 | 脂質ナノ粒子製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240358652A1 (https=) |
| EP (1) | EP4387657A4 (https=) |
| JP (1) | JP2024534066A (https=) |
| AU (1) | AU2022328856A1 (https=) |
| WO (1) | WO2023019310A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024197098A2 (en) * | 2023-03-20 | 2024-09-26 | Cartesian Therapeutics, Inc. | Local conditioning of lymph nodes with diffusion-limited particles for in vivo car therapy |
| CN116271105B (zh) * | 2023-05-18 | 2023-08-25 | 上海贝斯昂科生物科技有限公司 | 一种适于rpe细胞转染的脂质纳米颗粒及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2542099A1 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| WO2014152211A1 (en) * | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP3160448B1 (en) * | 2014-06-26 | 2025-08-06 | Ramot at Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
| US20180085391A1 (en) * | 2014-08-08 | 2018-03-29 | Modernatx, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
| PL3386484T3 (pl) * | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| WO2017223135A1 (en) * | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Lipid nanoparticles |
| JP2022516318A (ja) * | 2019-01-04 | 2022-02-25 | オンコラス， インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
| EP3947646A1 (en) * | 2019-04-05 | 2022-02-09 | Precision BioSciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
| JP7589998B2 (ja) * | 2019-06-24 | 2024-11-26 | 国立大学法人北海道大学 | 脂質ナノ粒子 |
-
2022
- 2022-08-17 JP JP2024509404A patent/JP2024534066A/ja active Pending
- 2022-08-17 WO PCT/AU2022/050913 patent/WO2023019310A1/en not_active Ceased
- 2022-08-17 EP EP22857143.6A patent/EP4387657A4/en active Pending
- 2022-08-17 US US18/291,808 patent/US20240358652A1/en active Pending
- 2022-08-17 AU AU2022328856A patent/AU2022328856A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9415109B2 (en) | Stable non-aggregating nucleic acid lipid particle formulations | |
| US20230372245A1 (en) | Lipid formulations for nucleic acid delivery | |
| US10626393B2 (en) | Delivering CRISPR therapeutics with lipid nanoparticles | |
| US10077232B2 (en) | Cyclic cationic lipids and methods of use | |
| US20230212578A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
| US20130022649A1 (en) | Snalp formulations containing antioxidants | |
| US10415037B2 (en) | Compositions and methods for silencing hepatitis B virus gene expression | |
| JP2021059555A5 (https=) | ||
| JP2022184875A5 (https=) | ||
| US20220160899A1 (en) | Compositions and methods for delivering messenger rna | |
| US20110071208A1 (en) | Lipid encapsulated dicer-substrate interfering rna | |
| US20200282060A1 (en) | Novel cationic lipids and methods of use thereof | |
| EP3329003A2 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| WO2016183366A2 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| JP2024534066A5 (https=) | ||
| JP2025501764A5 (https=) | ||
| WO2023225621A2 (en) | Lipids for delivery of therapeutic agents | |
| US20220184113A1 (en) | RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF |